Promising developments in prion immunotherapy

Expert Review of Vaccines

Volumn 4, Issue 5, 2005, Pages 607-610

  Sigurdsson, Einar M ^a   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PRION PROTEIN; PRION PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALEUTIAN MINK DISEASE; ALZHEIMER DISEASE; ANTIBODY RESPONSE; BLOOD BANK; BOVINE SPONGIFORM ENCEPHALOPATHY; CHRONIC WASTING DISEASE; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; DISEASE CARRIER; DRUG DESIGN; DRUG TARGETING; EDITORIAL; EPIDEMIC; FATAL FAMILIAL INSOMNIA; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; KURU; NONHUMAN; ORGAN TRANSPLANTATION; PASSIVE IMMUNIZATION; PATHOGENESIS; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROVIRUS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; PRION DISEASES; PROTEIN STRUCTURE, SECONDARY; PRPC PROTEINS; VACCINES;

EID: 27444448236     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.5.607     Document Type: Editorial

References (33)

1. Aguzzi A, Heikenwalder M, Miele G. Progress and problems in the biology, diagnostics, and therapeutics of prion diseases. J. Clin. Invest. 114, 153-160 (2004).
2. Aucouturier P, Carp RI, Carnaud C, Wisniewski T. Prion diseases and the immune system. Clin. Immunol. 96, 79-85 (2000).
3. Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P, Schonberger LB. Chronic wasting disease and potential transmission to humans. Emerg. Infect. Dis. 10, 977-984 (2004).
4. Chesebro B. Biomedicine. A fresh look at BSE. Science 305, 1918-1921 (2004).
5. Collinge J. Molecular neurology of prion disease. J. Neurol. Neurosurg. Psychiatry 76, 906-919 (2005).
6. Feraudet C, Morel N, Simon S et al. Screening of 145 antiPrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J. Biol. Chem. 280, 11247-11258 (2005).
7. Gajdusek DC, Gibbs CJ Jr, Alpers M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 209, 794-796 (1966).
8. Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial. Neurol. 64, 1553-1562 (2005).
9. Goni F, Knudsen EL, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413-421 (2005). First paper to show active mucosal vaccination can protect prion model animals from infection via an oral route.
10. Griffith JS. Self-replication and scrapie. Nature 215, 1043-1044 (1967).
11. Heppner FL, Musahl C, Arrighi I et al. Prevention of scrapie pathogenesis by transgenic expression of antiprion protein antibodies. Science 294, 178-182 (2001).
12. Hilton DA, Ghani AC, Convers L et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J. Pathol. 203, 733-739 (2004).
13. Khalili-Shirazi A, Quaratino S, Londei M et al. Protein conformation significantly influences immune response to prion protein. J. Immunol. 174, 3256-3263 (2005).
14. Kimberlin RH, Walker CA. The role of the spleen in the neuroinvasion of scrapie in mice. Virus Res. 12, 201-212 (1989).
15. Ma J, Wollman R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298, 1781-1785 (2005).
16. Manuelidis L. Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc. Natl Acad. Sci. USA 95, 2520-2525 (1998). Shows that infection with one prion strain can prevent infection with a differenct strain.
17. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell 35, 57-62 (1983).
18. Nikles D, Bach P, Boller K et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J. Virol. 79, 4033-4042 (2005). Shows that exposure of mice to retrovirus particles expressing prion protein (PrP) can induce humoral immunity against native PrP.
19. Pan KM, Baldwin M, Njuyen J et al. Conversion of α-helices into β-sheets features in the formation of scrapie prion poteins. Proc. Natl Acad. Sci. USA 90, 10962-10966 (1993).
20. Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with antiprion protection. Proc. Natl Acad. Sci. USA 101, 14670-14676 (2004).
21. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
22. Roucou X, Guo Q, Zhang Y, Goodyer CG, LeBlanc AC. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278, 40877-40881 (2003).
23. Sadowski M, Wisniewski T. Vaccines for conformational disorders. Exp. Rev. Vaccines 3, 89-100 (2004).
24. Shmakov AN, Ghosh S. Prion proteins and the gut: une liason dangereuse? Gut 48, 443-447 (2001).
25. Sigurdsson EM, Brown DR, Daniels M et al. Vaccination delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17 (2002). First paper to show active immunization with PrP in wild-type mice can induce a humoral immune response that results in a prolongation of the incubation period of prion infection.
26. Sigurdsson EM, Knudsen EL, Asuni A et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J. Neurosci. 24, 6277-6282 (2004). Shows that use of nonfibrillogenic Aβ derivatives as active vaccines can lead to cognitive improvement in Alzheimers Disease model mice, despite relatively low antibody titers.
27. Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447 (2001).
28. Sigurdsson EM, Sy MS, Li R et al. AntiPrP antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett 336, 185-187 (2003).
29. Solforosi L, Criado JR, McGavern DB et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514-1516 (2004).
30. Spraker TR, Miller MW, Williams ES et al. Spongiform encephalopathy in free-ranging mule deer (Odocoileus hemionus) white-tailed deer (Odocoileus virginianus) and Rocky Mountain elk (Cervus elaphus nelsont) in northcentral Colorado. J. Wildl. Dis. 33, 1-6 (1997).
31. White AR, Enever P, Tayebl M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83 (2003). Shows that passive immunization with high dose anti-PrP antibody, given within a month of prion exposure, can protect against prion infection.
32. Wineland NE, Detwiler LA, Salman MD. Epidemiologic analysis of reported scrapie in sheep in the United States: 1,117 cases (1947-1992). J. Am. Vet. Med. Assoc. 212, 713-718 (1998).
33. Wisniewski T, Frangione B. Immunological and antichaperone therapeutic approaches for Alzheimer's disease. Brain Pathol. 15, 72-77 (2005).